You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2025

CLINICAL TRIALS PROFILE FOR FLUNISOLIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for flunisolide

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT02404103 ↗ Flunisolide HFA in Children With Small Airway Disease Completed Meda Pharmaceuticals N/A 2015-03-01 The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.
NCT02404103 ↗ Flunisolide HFA in Children With Small Airway Disease Completed University of Louisville N/A 2015-03-01 The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.
NCT00346775 ↗ Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Completed GlaxoSmithKline Phase 3 2006-05-01 The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn Milton S. Hershey Medical Center Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00203684 ↗ Mentored Patient-Oriented Research Career Development Award Unknown status University of California, Los Angeles Phase 1/Phase 2 1969-12-31 Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung). Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA). Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid. Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 6 of 6 entries

Clinical Trial Conditions for flunisolide

Condition Name

3111000.511.522.53AsthmaChildhood AsthmaDistal Lung InflammationLung Diseases[disabled in preview]
Condition Name for flunisolide
Intervention Trials
Asthma 3
Childhood Asthma 1
Distal Lung Inflammation 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

21110-0.200.20.40.60.811.21.41.61.822.2AsthmaPneumoniaInflammationPulmonary Disease, Chronic Obstructive[disabled in preview]
Condition MeSH for flunisolide
Intervention Trials
Asthma 2
Pneumonia 1
Inflammation 1
Pulmonary Disease, Chronic Obstructive 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for flunisolide

Trials by Country

+
Trials by Country for flunisolide
Location Trials
United States 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for flunisolide
Location Trials
California 3
Kentucky 1
Wisconsin 1
North Carolina 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for flunisolide

Clinical Trial Phase

50.0%25.0%25.0%0-0.200.20.40.60.811.21.41.61.822.2Phase 3Phase 1/Phase 2N/A[disabled in preview]
Clinical Trial Phase for flunisolide
Clinical Trial Phase Trials
Phase 3 2
Phase 1/Phase 2 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

50.0%25.0%25.0%0-0.200.20.40.60.811.21.41.61.822.2CompletedWithdrawnUnknown status[disabled in preview]
Clinical Trial Status for flunisolide
Clinical Trial Phase Trials
Completed 2
Withdrawn 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for flunisolide

Sponsor Name

trials0112233National Heart, Lung, and Blood Institute (NHLBI)University of LouisvilleMilton S. Hershey Medical Center[disabled in preview]
Sponsor Name for flunisolide
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 2
University of Louisville 1
Milton S. Hershey Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

42.9%28.6%28.6%000.511.522.53OtherIndustryNIH[disabled in preview]
Sponsor Type for flunisolide
Sponsor Trials
Other 3
Industry 2
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Flunisolide: Clinical Trials, Market Analysis, and Projections

Introduction to Flunisolide

Flunisolide is a synthetic corticosteroid used primarily in the treatment of respiratory conditions such as asthma, allergic rhinitis, and chronic rhinosinusitis. It is available in various formulations, including nasal sprays, aerosol inhalers, and solutions for inhalation.

Clinical Trials and Efficacy

Short-Term Efficacy and Safety

Clinical trials have demonstrated the efficacy and safety of flunisolide in managing respiratory conditions. A notable study involved 78 patients with perennial rhinitis who underwent a 12-week double-blind, placebo-controlled trial using flunisolide nasal spray. The results showed that flunisolide was safe and effective in reducing symptoms of perennial rhinitis without significant side effects or evidence of adrenal suppression over a 2-year follow-up period[4].

Long-Term Follow-Up

The long-term follow-up of patients treated with flunisolide has been positive. For instance, a study where 18 patients were followed up after the initial 12-week trial showed continued subjective benefit without serious side effects or adrenal suppression after 2 years of therapy[4].

Market Analysis

Current Market Size and Growth

The flunisolide market has been experiencing steady growth, driven by the increasing prevalence of respiratory conditions such as asthma and allergic rhinitis. In 2023, the market size for flunisolide was estimated to be around $0.44 billion, with projections indicating further growth through 2030[5].

Regional Market Trends

  • North America: This region dominates the flunisolide market, primarily due to high healthcare expenditure, a well-established pharmaceutical industry, and a strong focus on respiratory health. The U.S. leads in market share due to the high prevalence of asthma and allergic rhinitis[5].
  • Europe: Europe follows closely, with significant demand from countries like Germany, the UK, and France. The region benefits from high awareness of respiratory diseases and access to advanced treatments[5].
  • Asia-Pacific: This region is expected to witness the fastest growth, driven by increasing healthcare access, rising pollution levels contributing to respiratory issues, and growing awareness about treatment options in countries like China, India, and Japan[5].
  • Latin America and Middle East & Africa: These regions show moderate growth potential, with improving healthcare infrastructure and increasing awareness, though challenges such as limited access to advanced therapies and lower healthcare spending may hinder market expansion[5].

Market Drivers

The primary drivers of the flunisolide market include:

  • Rising Incidence of Chronic Respiratory Diseases: The increasing prevalence of asthma and chronic obstructive pulmonary disease (COPD) worldwide is a significant driver.
  • Growing Geriatric Population: The elderly are more susceptible to respiratory issues, further boosting demand.
  • Increasing Healthcare Spending: Improved access to medical facilities in emerging economies contributes to market growth.
  • Advanced Drug Delivery Systems: Innovations in delivery systems, such as metered-dose inhalers and nebulizers, enhance the efficacy and ease of use of flunisolide products[5].

Market Restraints

Despite the positive growth outlook, the flunisolide market faces several restraints:

  • Potential Side Effects: Long-term use of corticosteroids like flunisolide can lead to adverse effects, which may result in patient non-compliance.
  • Alternative Therapies: The availability of alternative therapies and generic versions of flunisolide poses a challenge.
  • Stringent Regulatory Requirements: These requirements can delay the introduction of new and improved flunisolide formulations[5].

Market Segmentation

Formulation Outlook

Flunisolide is available in various formulations, including:

  • Nasal Spray
  • Aerosol Inhaler
  • Nasal Drops
  • Solution for Inhalation
  • Injection[5].

Application Outlook

The primary applications of flunisolide include:

  • Allergic Rhinitis
  • Nasal Polyps
  • Chronic Rhinosinusitis
  • Hay Fever
  • Asthma[5].

Strength Outlook

Flunisolide is available in various strengths, such as 25 mcg, 50 mcg, 100 mcg, 250 mcg, and 500 mcg[5].

Distribution Channel Outlook

The distribution channels for flunisolide include:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics[5].

Key Players in the Flunisolide Market

The market is dominated by several key players, including:

  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Novartis AG
  • AstraZeneca
  • Sanofi
  • Daiichi Sankyo Co., Ltd.
  • Pfizer Inc.
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Merck Co., Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline[5].

Emerging Trends and Innovations

The flunisolide market is witnessing a shift towards more convenient and user-friendly delivery systems. Innovations in metered-dose inhalers and nebulizers are gaining popularity among patients and healthcare providers. Additionally, there is a growing focus on early and consistent management of respiratory issues, which has led to higher demand for flunisolide-based treatments[5].

Competitive Landscape

The competitive landscape of the flunisolide market is shaped by the strategies of key players, including the development of advanced drug delivery systems, expansion into emerging markets, and the introduction of new formulations. The market is highly competitive, with multiple players vying for market share through innovative products and strong distribution networks[5].

Projections and Future Outlook

The flunisolide market is projected to continue its growth trajectory through 2030, driven by the increasing prevalence of respiratory conditions and advancements in drug delivery systems. The Asia-Pacific region is expected to be a key growth area due to rising healthcare access and growing awareness about treatment options.

"The global flunisolide market is predicted to increase from $0.44 billion in 2023 to reach a significant value by 2030, at a compound annual growth rate (CAGR) during the forecast period of 2025 through 2030"[5].

Key Takeaways

  • Clinical Efficacy: Flunisolide has been proven safe and effective in clinical trials for managing respiratory conditions.
  • Market Growth: The market is driven by the rising incidence of chronic respiratory diseases and advancements in drug delivery systems.
  • Regional Trends: North America and Europe are current leaders, while the Asia-Pacific region is expected to show the fastest growth.
  • Market Restraints: Potential side effects and stringent regulatory requirements are key challenges.
  • Key Players: Multiple pharmaceutical companies are driving the market through innovative products and strong distribution networks.

FAQs

What are the primary drivers influencing the growth of the flunisolide market?

The primary drivers include the rising incidence of chronic respiratory diseases, a growing geriatric population, increasing healthcare spending, and advancements in drug delivery systems.

How do regional trends affect the demand for flunisolide?

Regional trends significantly impact demand, with North America and Europe currently leading due to high healthcare expenditure and awareness of respiratory diseases. The Asia-Pacific region is expected to show the fastest growth due to increasing healthcare access and rising pollution levels.

Which key players are leading the flunisolide market, and what are their strategies?

Key players include Johnson & Johnson, Astellas Pharma Inc., Novartis AG, and others. Their strategies include developing advanced drug delivery systems, expanding into emerging markets, and introducing new formulations.

What are the emerging trends and innovations in the flunisolide market?

Emerging trends include a shift towards more convenient and user-friendly delivery systems, such as metered-dose inhalers and nebulizers, and a growing focus on early and consistent management of respiratory issues.

How does the competitive landscape shape the flunisolide market?

The competitive landscape is shaped by the strategies of key players, including the development of advanced drug delivery systems, expansion into emerging markets, and the introduction of new formulations, leading to a highly competitive market.

Sources

  1. Clinical Study Protocol (CSP) - ClinicalTrials.gov
  2. Global Flunisolide Market Insights, Forecast to 2030 - QYResearch
  3. Clinical Review(s) - accessdata.fda.gov
  4. Short-term efficacy trial and twenty-four-month follow-up of ... - PubMed
  5. Flunisolide Market Capitalize on the --- Boom: Top Companies & Trends to Watch (2024-2032) - OpenPR

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.